NovaBay Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 3957.2%.

Top 19 shareholders own 0.34% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
0.17%	UBS Asset Management AG	8,158	€3.8k	29.4%	no data
0.087%	Tian Tian Limited	4,235	€2.0k	0%	no data
0.067%	Tower Research Capital Europe Limited	3,293	€1.5k	659%	no data
0.012%	Fgp Protective Opportunity Master Fund	571	€264.6	0%	100.0%
0.0016%	Paul Freiman	77	€35.8	2.67%	no data
0.0015%	Swan Sit	75	€34.9	0%	no data
0.0015%	Yenyou Zheng	75	€34.9	0%	no data
0.0015%	Mijia Wu	75	€34.9	0%	no data
0.0014%	Justin Hall	68	€31.5	0%	no data
0.001%	Yongxiang Zheng	50	€23.1	0%	no data
0.001%	Julie Garlikov	50	€23.1	0%	no data
0.00086%	Bank of America Corporation, Asset Management Arm	42	€19.5	2,000%	no data
0.00076%	Thrivent Trust Company, Asset Management Arm	37	€17.2	3,600%	no data
0.00006%	Morgan Stanley, Investment Banking and Brokerage Investments	3	€1.4	-25%	no data
0.00006%	NVWM LLC	3	€1.4	50%	no data
0.00002%	RBC Dominion Securities Inc., Asset Management Arm	1	€0.5	0%	no data
0.00002%	Northwestern Mutual Wealth Management Company	1	€0.5	0%	no data
0.00002%	Securities America Advisors, Inc.	1	€0.5	0%	no data
0.00002%	Addison Advisors LLC	1	€0.5	0%	no data